↓ Skip to main content

Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease

Overview of attention for article published in BMC Neurology, October 2021
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)
  • High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

twitter
19 X users

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
52 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease
Published in
BMC Neurology, October 2021
DOI 10.1186/s12883-021-02430-2
Pubmed ID
Authors

S. Neumann, J. Taylor, A. Bamford, C. Metcalfe, D. M. Gaunt, A. Whone, D. Steeds, S. R. Emmett, W. Hollingworth, Y. Ben-Shlomo, E. J. Henderson

X Demographics

X Demographics

The data shown below were collected from the profiles of 19 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 52 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 6 12%
Researcher 3 6%
Student > Ph. D. Student 3 6%
Lecturer 2 4%
Unspecified 2 4%
Other 4 8%
Unknown 32 62%
Readers by discipline Count As %
Medicine and Dentistry 6 12%
Neuroscience 4 8%
Unspecified 2 4%
Psychology 2 4%
Biochemistry, Genetics and Molecular Biology 1 2%
Other 4 8%
Unknown 33 63%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 March 2023.
All research outputs
#2,436,741
of 25,248,299 outputs
Outputs from BMC Neurology
#241
of 2,680 outputs
Outputs of similar age
#53,951
of 435,680 outputs
Outputs of similar age from BMC Neurology
#10
of 69 outputs
Altmetric has tracked 25,248,299 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,680 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 435,680 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.